Study Title
ACNS1721: A Phase 2 Study of Veliparib (ABT-888, IND# 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
Protocol ID
ACNS1721
Condition/s
Anaplastic Astrocytoma
Glioblastoma
Malignant Glioma
Glioblastoma
Malignant Glioma
Diagnosis Stage
New diagnosis
Sponsor
National Cancer Institute (NCI)
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 2
Age Eligibility
3 Years to 25 Years
International registry ID's
NCT03581292
| Study Title | ACNS1721: A Phase 2 Study of Veliparib (ABT-888 IND# 139199) and Local Irradiation Followed by Maintenance Veliparib and Temozolomide in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations |
|---|---|
| Protocol ID | ACNS1721 |
| Disease (Sub Disease) | Anaplastic Astrocytoma Glioblastoma Malignant Glioma |
| Diagnosis Stage | New diagnosis |
| Sponsor | National Cancer Institute (NCI) |
| Links | https://clinicaltrials.gov/ct2/show/NCT03581292 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 31/10/2018 |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 3 Years to 25 Years |
| International registry ID's | NCT03581292 |